Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Status:
RECRUITING
Trial end date:
2031-03-01
Target enrollment:
Participant gender:
Summary
It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.
Phase:
PHASE2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Anhui Provincial Cancer Hospital Beijing Friendship Hospital Cancer Hospital of Guangxi Medical University Gansu Provincial Maternal and Child Health Care Hospital Qilu Hospital of Shandong University Shengjing Hospital Sichuan Cancer Hospital and Research Institute Southwest Hospital, China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Tianjin Medical University General Hospital West China Second University Hospital Women's Hospital School Of Medicine Zhejiang University Xiangya Hospital of Central South University Zhejiang Cancer Hospital